Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05357352 · ClinicalTrials.gov registry record
Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis
A clinical trial of Non-alcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis, sponsored by Methodist Health System.
- Completed
- Registry status
- 263
- Enrollment target
- 1
- Study location
NCT05357352: Completed study of Non-alcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis, sponsored by Methodist Health System.
NCT05357352 is a study of Non-alcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis that has completed, run by Methodist Health System. The registered enrollment target is 263 participants, above the 173-participant average among 57 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (52% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05357352, a study of Non-alcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis, has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 263 participants
- Enrollment target
- 1
- Study location
Study Summary
Few studies have evaluated an extensive list of possible risk factors for NAFLD for their association with presence and severity of histologic features. We wish to conduct a retrospective study on these possible factors (including demographics, comorbid diseases, and medications) for their association, if any, with severity of histopathologic findings. This study hypothesize that certain risk factors, specifically those contributing to or consisting of metabolic syndrome, will have higher NASH Fibrosis stages.
Primary Outcome
Severity of Nonalcoholic fatty liver disease and fibrosis staging. The NAS is a measure of grade and is the sum of numerical scores applied to steatosis (0-3), hepatocellular ballooning (0-2), and lobular inflammation (0-3). Accordingly, the NAS ranges from 0 to 8 (see Table 12.3). The NAS is one of the few grading systems for NAFLD that has been externally validated.
Conditions Studied
Interventions
- OTHER NAFLD/NASH
Study Locations (1)
Texas
- Methodist Dallas Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2019-05-24 |
| Est. Completion | 2021-04-07 |
What the finished NCT05357352 record still lists
NCT05357352 is an observational study that tracks outcomes without assigning an intervention. The registered 263 participants enrollment target is mid-sized for trials with a published cap, above the 173-participant average among 57 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (52% higher).
The record links to 2 conditions, with Non-alcoholic Fatty Liver Disease appearing as the primary indexed condition, and to 1 intervention - of which NAFLD/NASH is the first listed.
NCT05357352 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05357352 about?
NCT05357352 is a clinical study titled "Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis". Few studies have evaluated an extensive list of possible risk factors for NAFLD for their association with presence and severity of histologic features. We wish to conduct a retrospective study on these possible factors (including demographics, comorbid diseases, and medications) for their associati...
What is the current status of trial NCT05357352?
This trial is currently completed. The enrollment target is 263 participants. The study started on 2019-05-24. Estimated completion is 2021-04-07.
What conditions does trial NCT05357352 study?
This clinical trial studies the following conditions: Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis.
What interventions are being tested in trial NCT05357352?
The interventions under investigation include: NAFLD/NASH (OTHER).
Who is sponsoring clinical trial NCT05357352?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05357352 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Fatty Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05357352's enrollment target sits among peer trials
263 9th of 57 higher than 49 of 57 other Non-alcoholic Fatty Liver Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-alcoholic Fatty Liver Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
RECRUITING · Phase 3
-
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
RECRUITING · Phase 3
-
Intermittent Fasting for NAFLD in Adults
RECRUITING · NA
-
Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents
RECRUITING · NA
-
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
RECRUITING
-
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04067336 · 263 participants · Phase 1
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
- NCT06234423 · 263 participants · Phase 1
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
- NCT06724627 · 263 participants · NA
Application of the Belle.AI Dermatological Image Reference System for Patient Diagnosis in an Active Clinical Setting
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI